<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences Announces Addition of Cancer Suite

Posted by MD Biosciences on Jan 28, 2016 4:28:59 PM

ST. PAUL, Minnesota - January 25, 2016 - MD Biosciences (mdbiosciences.com) today announced the addition of its suite of in vivo and in vitro cancer models to its family of preclinical contract research services. MD Biosciences' oncology research program specializes in murine solid tumors for subcutaneous and orthoptopic models (for example, advanced breast cancer and renal cancer) with a specific focus on the immune aspects of disease development and progression. The comprehensive services include both syngeneic and xenograft models with readouts for longitudinal tumor monitoring (for some models), longitudinal blood phenotyping (immune cell distribution, biomarkers, etc.), endtime-point primary/metastic tumor evaluation, tumor tissue-specific cellular analysis using intravascular staining (cells: epithelial, endothelial, immune, etc.), biomarker analysis (blood, tumor, tissue, spleen, lymph node, etc.) and histological grading and evaluation of tumor specific issue (H&E, IHC, etc.).

"Our onco-immunology research team is comprised of skilled scientists with deep-rooted expertise in a highly complex field," said Eddie Moradian, MD Biosciences CEO. "We at MD Biosciences are excited to bring our high level of expertise and our novel models to assist sponsors and partners in reaching their programs' developmental goals. This new suite of capabilities compliments our existing, best-in-class services in other disease areas.


About MD Biosciences

MD Biosciences is a leading provider of preclinical services in the core areas of inflammation, immunological, neurologoical and metabolic diseases. The suite of services includes a wide range of cell-bassed assays, in vivo disease models, translational models as well as models for the indentification of the mode of action of drugs. The services are supported by CLIA accredited and GLP in vitro diagnostic laboratories for the testing of samples by using genomic and proteomic methods. MD Biosciences' in vitro laboratories provide services for the testing of clinical samples. Proprietary models include pig models for neuropathic pain, would healing and other key disease areas.


Read More

Topics: news, in vivo pain models, cancer/tumor, contract research

MD Biosciences Syngeneic Tumor Models for Primary Orthotopic & Metastasis.

Posted by MD Biosciences on Oct 1, 2013 8:46:00 AM

syngeneic tumor models MDBiosciencesMD Biosciences releases a new line of in vivo syngeneic tumor models for the study of primary orthotopic tumors and metastasis. The basis of the syngeneic tumor model is that it uses tumor cells that are injected into either the organ of origin or into the systemic circulation of a host that is of the same species and genetic background as the tumor cells or tissue originated from. Additionally, syngeneic tumor models offer the advantage of a short latency time and increased phenotype reproducibility due to injecting a controlled number of cells.

Syngenic tumor models are excellent preclinical models for studying the interaction of tumor cells with the host immune system as well as the impact of tumors on local and systemic factors such as the surrounding tissue and the vascular system. They utilize injected tumor cells or tissue from the same species and genetic background as the host, which permits the assessment of compatible tumor-stroma microenvironmental interactions, endocrine signaling and immune responses. Unlike xenotransplantation models where the hosts are immunocompromised to enable the innoculation of human tumors or cells into murine hosts without rejection, syngenic tumor models utilize immuocompetent hosts allowing immune-cell-tumor-cell interactions. This is critical as a functioning immune system is the backbone of studies involving cytotoxic T cells, Tregs, tumor-associated macrophages, cell trafficking or inflammatory fibrotic stromal reactions. Additionally, the effects of an intact immune system on the onset of metastasis and progression are important.

Orthotopic Tumor models are created on the basis of injecting tumor cells directly into the organ of origin and exhibit organotypical interactions between the tumor cells and the surrounding stroma. These interactions affect the growth, differentiation and drug sensitivity of the tumor cells.

  • Breast Cancer
  • Liver Cancer/Hepatocellular carcinoma (HCC)
  • Neuroblastoma
  • Pancreatic Cancer

Metastasis Models are created on the basis of injecting tumor cells directly to the systemic circulation. The site of injection will largely dictate which metastasis will develop as the cells will arrest in the first capillary bed encountered.

  • Pulmonary metastasis
  • Hepatic metastasis


MD Biosciences research group is actively involved in developing approaches, methods and models that bring greater translational relevance to the clinical situation. With a high failure rate in the clinical trial phase of drug development, more relevant models are needed that provide greater translation to the clinic.


About MD Biosciences

MD Biosciences is a leading preclinical research group and contract research organization (CRO) working with biopharmaceutical and medical device companies in an effort towards progressing discovery and development programs to clinical stages. We are deeply focused on inflammatory, neurodegenerative/CNS, pain, dermal, metabolic and cardiovascular conditions with a particular emphasis on the interplay between the immune, nervous and cardiovascular systems and the conditions that arise in the cross talk between them. We bring decisive value to preclinical programs with the extensive experience gained over many years of handling different compound classes through all administration routes aimed at numerous therapeutic indications.



The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.


Read More

Topics: cancer/tumor